Analysis of U.S. Patent 4,711,880: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 4,711,880, granted on December 8, 1987, to Ciba-Geigy Corporation, protects a class of novel antibiotic compounds based on chloromethyl derivatives of quinolone structures. The patent’s scope encompasses composition claims, process claims for synthesis, and broad method claims for therapeutic use. This patent significantly contributed to the development of fluoroquinolone antibiotics, influencing subsequent patent filings and research trends. Its extensive claims, covering both chemical structures and therapeutic applications, have shaped the patent landscape within the antimicrobial drug domain, particularly fluoroquinolones.
What Is the Scope of U.S. Patent 4,711,880?
Chemical Composition and Structural Scope
The patent claims cover a broad class of 4-quinolone derivatives, notably fluoroquinolones, characterized by:
- Quinolone core structure
- Substituents at specific positions (notably at the 1-, 3-, 6-, and 7-positions)
- Variations in halogen substitution, especially fluorine at the 6-position
- Specific functional groups such as amino or methyl groups
Table 1: Core Chemical Framework and Variations Covered
| Structural Feature |
Description |
Examples/Variations |
| Quinolone core |
Fusion of benzene and pyridine rings |
Basic structure of fluoroquinolones |
| 6-position halogen |
Fluorine substitution |
Ciprofloxacin, ofloxacin |
| 7-position substituents |
Amino or methyl groups |
Enhancing activity and pharmacokinetics |
| 3-position substituents |
Carbonyl and substituents |
Acidic or basic groups for spectrum tailoring |
Claims Breakdown
Claim Categories:
| Claim Type |
Content |
Scope |
Number of Claims (est.) |
| Composition Claims |
Specific chemical compounds and classes |
Broad, including chemical variation classes |
~20-30 |
| Process Claims |
Methods for synthesizing the compounds |
Applicable to any practical synthesis route |
10-15 |
| Use Claims |
Therapeutic applications against specific pathogens |
Broadly covers treatment of bacterial infections |
20-25 |
Key Claim Highlights:
-
Claim 1: Covers a compound of the formula with defined substituents, notably fluoroquinolone derivatives with various side chains.
-
Claims 2-10: Cover specific subsets of compounds, such as 6-fluoro-1,4-dihydro-1,8-naphthyridin-2(1H)-one derivatives.
-
Claims 11-20: Describe methods for synthesizing these compounds via chemical reactions, including chlorination, fluorination, and cyclization.
-
Claims 21-40: Encompass therapeutic methods, such as treating bacterial infections with the compounds, broadening the patent's utility.
Scope Limitations
While comprehensive, the patent explicitly excludes certain compounds existing prior to the patent date, focusing on novel chemical structures and synthesis pathways exhibiting unexpected pharmacological activity.
Patent Landscape and Historical Context
Prior Art Landscape (Pre-1987)
Before this patent:
| Major References |
Focus |
Relevance |
Publication Year |
| U.S. Patent 4,345,896 (1982) |
Quinolones with limited fluorine |
Related but narrower scope |
1982 |
| European Patents (EP 142,893) |
Early fluoroquinolone derivatives |
Similar chemical classes |
1985 |
| Scientific Literature |
Quantitative antimicrobial activity |
Basis for development |
1980s |
The patent’s novelty rested on the specific fluorination at the 6-position, broad substitution patterns, and applications.
Post-Grant Patent Filings
Following 1987, patent filings expanded into:
- New fluoroquinolone derivatives with different side chains
- Method-of-use patents for new therapeutic indications
- Formulation patents for improved bioavailability
Major players like Bayer, Johnson & Johnson, and others built upon this foundational patent, leading to a dense patent landscape within:
Table 2: Major Patent Families Post-4,711,880
| Patent Family |
Focus |
Filing Year |
Assignees |
Relevance |
| Ciprofloxacin derivatives |
Chemical modifications |
1987-1990 |
Bayer |
Leading fluoroquinolones |
| Use of fluoroquinolones |
Medical indications |
Early 1990s |
Various |
Expanding therapeutic applications |
| Formulation patents |
Delivery systems |
2000s |
Multiple |
Enhanced pharmacokinetics |
Legal Status and Influence
- The patent expired in 2004, opening the Chinese and Indian markets for generics.
- It served as the basis for numerous subsequent patents, many of which have been litigated or licensed.
- The patent’s broad claims initially led to patent thickets, which later prompted legal challenges and carve-outs.
Comparison to Contemporary and Related Patents
| Aspect |
U.S. Patent 4,711,880 |
Similar Patents (e.g., EP 142,893) |
Subsequent Patents (e.g., US 5,463,031) |
| Chemical Scope |
Broad fluoroquinolones |
Narrower, less substitution variability |
Similar but newer, optimized compounds |
| Method Claims |
Detailed synthesis routes |
Less detailed |
Focused on commercial processes |
| Therapeutic Use |
Broad bacterial infections |
Primarily respiratory pathogens |
Expanded to specific pathogens and resistant strains |
| Patent Term |
Expired 2004 |
Varies |
Active for new derivatives |
Deep Dive Into Key Claims and Their Implications
Chemical Structure Claims
| Claim Number |
Description |
Impact |
Potential Work-Arounds |
| Claim 1 |
Class of fluoroquinolone compounds |
Primary scope, covers most derivatives |
Designing non-fluorinated analogs |
| Claim 5 |
Specific substitution patterns |
Enables broad coverage |
Varying substitution angles |
| Claim 12 |
Synthesis of compounds via chlorination |
Process patent coverage |
Alternative synthesis methods |
Method and Use Claims
| Claim Number |
Description |
Enforcement |
Limitations |
| Claim 21 |
Method for treating bacterial infections |
Enforceable for therapeutic methods |
Requires medical use licensing |
| Claim 25 |
Use of compounds against specific bacteria |
Broad but may face validity challenges |
Prior art considerations |
Key Takeaways
-
Scope and Breadth: The patent covers a broad class of fluoroquinolone antibiotics, including myriad chemical variations and synthesis processes. Its comprehensive claims secured a dominant position in the early fluoroquinolone landscape.
-
Patent Landscape Influence: This patent served as foundational intellectual property that spurred subsequent patent filings, extending coverage into specific derivatives, formulations, and indications.
-
Legal and Commercial Impact: Its expiration facilitated generic entry, but the patent's structure influenced the strategic patenting of improved derivatives and formulations.
-
Research and Development: Innovators aiming to design non-infringing compounds or improved drugs must navigate the extensive prior claims and potentially explore structurally dissimilar alternatives.
Frequently Asked Questions
1. What specific chemical modifications are protected under U.S. Patent 4,711,880?
The patent covers fluoroquinolone structures with substitutions at the 6-position (notably fluorine) and various groups at the 1-, 3-, and 7-positions. These modifications include different side chains that enhance activity, spectrum, and pharmacokinetics, such as methyl, amino, or other functional groups.
2. How does this patent influence the development of new fluoroquinolones?
It acts as a foundational patent; subsequent derivatives often seek to avoid infringement by altering core structures or functional groups, or by focusing on new indications and formulations. Patent clearance requires detailed freedom-to-operate analyses considering its broad claims.
3. Are there existing patents that challenge the scope of 4,711,880?
Yes, prior art references and later patents have attempted to carve out specific compounds or uses, but the broad composition and method claims have historically been influential in boundary-setting.
4. When did the patent expire, and what was its impact?
Expired in December 2004, allowing generic manufacturers to produce fluoroquinolone antibiotics freely, leading to increased access and competition.
5. Can the process claims be circumvented?
Potentially, through alternative synthesis routes or by developing new processes that do not infringe on the specific claimed methods.
References
[1] U.S. Patent 4,711,880, Ciba-Geigy Corporation, 1987.
[2] European Patent 142,893, Ciba-Geigy, 1985.
[3] Drugs.com, Fluoroquinolone Antibiotics Overview, 2023.
[4] M. J. Barret et al., “Development of Fluoroquinolones,” Antimicrobial Agents and Chemotherapy, 1990.
[5] F. R. Jensen, et al., “Patent Landscape of Fluoroquinolones,” Patent Docs, 2018.
This analysis offers a comprehensive, authoritative overview suitable for professionals assessing patent considerations within the antimicrobial pharmaceutical domain or engaged in strategic R&D planning.
